Endowment Wealth Management’s Humacyte HUMA Stock Holding History

Endowment Wealth Management’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$82.2K	Hold	105,418	–	–	0.03%	174
2026 Q1	$64.3K	Sell	105,418 -495	-0.5%	-$515	0.03%	161
2025 Q4	$96.8K	Sell	105,913 -3,545	-3%	-$5.02K	0.04%	147
2025 Q3	$190K	Hold	109,458	–	–	0.09%	150
2025 Q2	$192K	Buy	109,458 +5,350	+5%	+$10.3K	0.1%	147
2025 Q1	$178K	Hold	104,108	–	–	0.11%	140
2024 Q4	$626K	Buy	104,108 +3,590	+4%	+$17.8K	0.42%	59
2024 Q3	$485K	Hold	100,518	–	–	0.32%	67
2024 Q2	$482K	Buy	100,518 +3,000	+3%	+$15.6K	0.35%	68
2024 Q1	$303K	Hold	97,518	–	–	0.23%	94
2023 Q4	$319K	Hold	97,518	–	–	0.27%	86
2023 Q3	$286K	Hold	97,518	–	–	0.26%	96
2023 Q2	$319K	Buy	97,518 +900	+0.9%	+$3.24K	0.29%	91
2023 Q1	$299K	Hold	96,618	–	–	0.3%	87
2022 Q4	$204K	Hold	96,618	–	–	0.22%	116
2022 Q3	$315K	Hold	96,618	–	–	0.38%	71
2022 Q2	$310K	Hold	96,618	–	–	0.37%	69
2022 Q1	$682K	Hold	96,618	–	–	0.72%	24
2021 Q4	$700K	Buy	+96,618	New	+$956K	0.71%	28

Other funds holding HUMA

Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Endowment Wealth Management's HUMA Position: Q2 2026 in Review

Endowment Wealth Management held its Humacyte (HUMA) position steady in Q2 2026 at 105,418 shares worth $82.2K. The position accounts for 0.03% of the portfolio, ranked #174.

Endowment Wealth Management first reported a position in HUMA in Q4 2021 and has held it in 19 quarters since. The position peaked at $700K in Q4 2021. 161 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

Endowment Wealth Management held 105,418 shares of Humacyte worth $82.2K as of Q2 2026.
Endowment Wealth Management left its Humacyte share count unchanged in Q2 2026.
Humacyte made up 0.03% of Endowment Wealth Management's portfolio in Q2 2026, its #174 holding.
Endowment Wealth Management first reported a position in Humacyte in Q4 2021 and has held it in 19 quarters since.
Endowment Wealth Management's Humacyte position peaked at $700K in Q4 2021.
161 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Endowment Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.